Strategically targeting MYC in cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The MYC oncoprotein drives cancer progression by regulating genes involved in cell growth, proliferation, metabolism, and survival.
• Targeting MYC is a key strategy in cancer therapy, with various compounds developed to inhibit its function or stability.
• Direct MYC inhibitors targeting the MYC-MAX interaction have shown limitations in pharmacokinetic and pharmacodynamic properties for in vivo use.

Purpose of the Study:

• To review the development of compounds that indirectly inhibit MYC.
• To highlight the therapeutic potential of novel MYC-targeting agents in MYC-driven cancers.

Main Methods:

• Review of recent studies on compounds inhibiting MYC transcription.
• Analysis of indirect inhibition strategies targeting transcription factors.

Main Results:

• Two compounds, JQ1 and THZ1, indirectly inhibit MYC by targeting unique transcription stages.
• These compounds demonstrate therapeutic value in MYC-driven cancers, though some effects may be MYC-independent.
• Current indirect inhibition approaches provide a basis for developing new anti-cancer drugs.

Conclusions:

• Indirect inhibition of MYC through transcription targeting represents a promising therapeutic strategy.
• Novel compounds targeting MYC transcription hold potential for treating various cancers.
• Further research into MYC-targeting agents is essential for advancing cancer therapy.